Skip to main content
. 2019 May;25(5):10.18553/jmcp.2019.25.5.510. doi: 10.18553/jmcp.2019.25.5.510

TABLE 2.

Health Care Sector Cost-Effectiveness Results for the Biologics

Annual Price, $a Cost per QALY, $
Omalizumab 28,900 325,000
Mepolizumab 29,500 344,000
Reslizumab 28,900 391,000
Benralizumab 27,800 371,000
Dupilumab 31,000 351,000

aAverage annual price of each treatment, net of discounts and rebates, as reported to ICER by each manufacturer.

ICER = Institute for Clinical and Economic Review; QALY = quality-adjusted life-year.